An experimental drug that lowers a blood protein linked to heart attacks and strokes did not protect patients in a large clinical trial, researchers reported Saturday.

Steven Nissen, a cardiologist at the Cleveland Clinic who led the study, said he was "shocked" by the result. He said he had "high hopes for success." The study enrolled 8,350 adults who already had heart disease. They received either a placebo or pelacarsen, a drug that targets lipoprotein(a), or Lp(a).

The drug reduced Lp(a) levels by about 78%, according to the researchers. After five years, however, that drop did not prevent cardiovascular complications. Nissen presented first details at an American Heart Association meeting in Chicago and published more specifics in the New England Journal of Medicine and NEJM Evidence.

Drugmaker Novartis, which sponsored the study, said last month that the results had not met its goals. In a statement, the company said the study "provides meaningful evidence" about the relationship between Lp(a) and heart disease.

Researchers offered several explanations for the outcome. Harlan Krumholz of Yale University said the result was "really jarring" given high expectations. Roger Blumenthal of Johns Hopkins University suggested that treatment may need to start earlier or last longer. David Maron of Stanford University suggested that patients with higher Lp(a) levels may need to be enrolled. Other experts raised the possibility that Lp(a) is a marker for another risk factor rather than a direct cause. Karol Watson of the University of California, Los Angeles said the story is "kind of just starting," because Amgen and Eli Lilly are testing other Lp(a)-lowering drugs.